NanoSight Receives £925,000 in Funding Round to Expand their Nanoparticle Characterization Business
News Nov 06, 2008
NanoSight Limited, the nanoparticle characterization company, has announced the completion of a new round of financing which will provide £925,000 to enable the company to expand the business with the development of new products and sales channels in the US market.
NanoSight has just closed almost £1m of investment finance in a month that has seen unprecedented financial turmoil worldwide. Having been close to breakeven for the first half of 2008, hitting sales targets and with margins better than anticipated, it was clear to the company that growth was limited by resource but not by market opportunity.
Having successfully weathered the start-up process during the past four years, NanoSight can become more robust with investment in personnel, technical support and development of the underlying technology, the company says.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019